A randomised, double-blind, placebo-controlled study to evaluate the efficacy of two different dose levels of orvepitant (10 and 30 mg) compared with placebo on EGFRi-induced intense pruritus in oncology subjects (The RELIEVE 1 Study)

Trial Profile

A randomised, double-blind, placebo-controlled study to evaluate the efficacy of two different dose levels of orvepitant (10 and 30 mg) compared with placebo on EGFRi-induced intense pruritus in oncology subjects (The RELIEVE 1 Study)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2015

At a glance

  • Drugs Orvepitant (Primary)
  • Indications Pruritus
  • Focus Therapeutic Use
  • Acronyms RELIEVE-1
  • Sponsors NeRRe Therapeutics
  • Most Recent Events

    • 19 Dec 2015 According to European Clinical Trials Database record, status changed from active, no longer recruiting to discontinued.
    • 24 Jun 2015 Status changed from recruiting to active, no longer recruiting, as per UKCRN record.
    • 06 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top